NASH on the Cusp: An Emerging Market Opportunity [BioSpace]
https://www.biospace.com/article/nash-on-the-cusp-an-emerging-market-opportunity-/
As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study [Endpoints]
https://endpts.com/as-it-awaits-key-readout-hepion-boosts-confidence-in-nash-drug-hopeful-via-shorter-study/
Fatty Liver, NASH, Cirrohosis – Can They Be Stopped??? [BioTech Nation]
https://www.biotechnation.com/episodes/fatty-liver-nash-cirrohosis-can-they-be-stopped
GEN2 NASH Therapies Near the Finish Line [Biospace]
https://www.biospace.com/article/gen2-nash-therapies-near-the-finish-line-/
What I Learned As CEO The First Time Around [Life Science Leader]
https://www.lifescienceleader.com/doc/what-i-learned-as-ceo-the-first-time-around-0001
Hepion Pharmaceuticals’ Lead Therapy, Rencofilstat [Oncology Tube]
https://oncologytube.com/v/41256#gsc.tab=0
Hepion Pharma’s Liver Cancer Candidate Secures Orphan Drug Tag [Markets Insider]
https://markets.businessinsider.com/news/stocks/the-daily-biotech-pulse-thumbs-down-for-acadia-s-pimavanserin-pfizer-buys-stake-in-valneva-astrazeneca---ionis-eplontersen-aces-rare-disease-trial-1031540289
FDA grants orphan drug designation to rencofilstat for hepatocellular carcinoma [Healio]
https://www.healio.com/news/hematology-oncology/20220620/fda-grants-orphan-drug-designation-to-rencofilstat-for-hepatocellular-carcinoma
FDA Grants Orphan Drug Designations to VBI, Hepion Cancer Drugs [BioSpace]
https://www.biospace.com/article/fda-approves-orphan-drug-designations-for-vbi-hepion-cancer-drugs/
Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor [Pharma’s Almanac]
https://www.pharmasalmanac.com/articles/tackling-liver-disease-with-a-multimodal-cyclophilin-inhibitor?hs_preview=FMelfVXS-74910818711
